NASDAQ: ANTXAn2 Therapeutics Inc Stock
$1.24+0.02 (+1.64%)
Updated Apr 30, 2025
AN2 Therapeutics shares are trading... find out Why ANTX Price Moved with a free WallStreetZen account
Why Price MovedANTX Price
$1.24
Fair Value Price
N/A
Market Cap
$37.32M
52 Week Low
$0.87
52 Week High
$3.07
P/E
-0.72x
P/B
0.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$51.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$49M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ANTX Overview
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develop treatments for rare, chronic, and infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company uses boron chemistry for its research and development initiatives. AN2 was incorporated in 2017 and is headquartered in Menlo Park, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANTX's potential to beat the market
- ANTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ANTX
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ANTX news, forecast changes, insider trades & much more!
ANTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ANTX is good value based on its book value relative to its share price (0.46x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
ANTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ANTX due diligence checks available for Premium users.
Valuation
ANTX fair value
Fair Value of ANTX stock based on Discounted Cash Flow (DCF)
Price
$1.24
Fair Value
$0.66
Overvalued by
87.03%
ANTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.72x
Industry
-162.28x
Market
29.18x
ANTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
4.45x
ANTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.5M
Profit Margin
0%
ANTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$92.1M
Liabilities
$10.2M
Debt to equity
0.13
ANTX's short-term assets ($86.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANTX's short-term assets ($86.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.3M
Investing
-$6.9M
Financing
$0.0
ANTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANTX vs Biotech Stocks
An2 Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.